



### Demographics and socioeconomic

Total Population (in 1000) (2020)	32,971.85
Population <1 year of age (in 1000) (2020)	620.71
Population 1 year of age (in 1000) (2020)	585.55
Population <5 years of age (in 1000) (2020)	2,833.27
Women of childbearing age (in 1000) (2020)	25,533.62
Infant Mortality Rate (per 1000 live births) (2017)*	15.0
Gross national income (US\$ per capita) current value (2020)	6,010.0
National Health Expenditure Public (2018)	3.3
National Health Expenditure Private (2018)	1.9

\* survey

### Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 12 times in 2020.
- No information is available on spending on routine immunization financed using government funds.
- No information is available on spending on vaccine purchase financed using government funds.
- A national nominal electronic immunization registry is in place.


### Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1999
Hepatitis B	1998
HPV	2015
Influenza	2008
MMR1	2003
MMR2	2007
Pentavalent	1999
Pneumococcal Conjugate	2009
Rotavirus	2009
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	2001

### Immunization Schedule

PER	Doses					
	1	2	3	4	5	6
BCG	B					
HepB pediatric	B					
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP	M18	Y4				
Influenza pediatric	M6	M7	Y1	Y2		
IPV	M2	M4				
OPV	M6	M18	Y4			
MMR	M12	M18				
Pneumoco conjugate	M2	M4	M12			
Rotavirus	M2	M4				
Td	Y10	+M2	+M4			
Tdap						
HPV	Y10	+M6				

### Vaccination Coverage




### Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	45
AFP rate per 100,000 population <15 years old	0.55
% of cases with 1 adequate samples	69
% of cases investigated within <48 hours	64
% sites reporting	6


Measles-rubella (MR)	2020
Number of MR suspected cases	76
% of cases with adequate investigation	92
% of cases with adequate blood samples	82
% of samples received in laboratory <=5 days	55
% of laboratory samples results <=4 days	51




### Polio3 coverage and AFP rate per 100,000 children <15 years of age




### DTP3 coverage and number of reported diphtheria and pertussis cases




### Number of tetanus (no neonatal) and neonatal tetanus cases



### Proportion of municipalities by coverage range with DTP3 in children <1 years of age



### DTP1-DTP3 and DTP1-MMR1 Dropout Rate



**Legend**

- NB/nb-newborn
- M/m -month
- Y/y-year
- WCBA-women of childbearing age
- with stockout
- no stockout
- no data available

### Vaccine Stockout

PER	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes	●	●	●	●	●	●	●	●
BCG	●	●	●	●	●	●	●	●
Disposable syringes	●	●	●	●	●	●	●	●
DTP	●	●	●	●	●	●	●	●
HepB	●	●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●	●
Influenza	●	●	●	●	●	●	●	●
IPV	●	●	●	●	●	●	●	●
Measles	●	●	●	●	●	●	●	●
Pneumo. conjugate	●	●	●	●	●	●	●	●
Polio	●	●	●	●	●	●	●	●
Reconst. syringes	●	●	●	●	●	●	●	●
Rotavirus	●	●	●	●	●	●	●	●
Safety boxes	●	●	●	●	●	●	●	●
Tdap	●	●	●	●	●	●	●	●
TT	●	●	●	●	●	●	●	●
Yellow fever	●	●	●	●	●	●	●	●